HOME >> BIOLOGY >> NEWS
Leftover Fetal Cells May Affect Development Of Scleroderma

A National Institute of Allergy and Infectious Diseases (NIAID) grantee in Seattle has found experimental data to support a new hypothesis about the genesis of scleroderma, an autoimmune disorder that primarily affects middle-aged women.

J. Lee Nelson, M.D., and her colleagues report in the Feb. 21 issue of The Lancet, that women with scleroderma have significantly higher levels of non-self fetal cells circulating in their blood decades after pregnancy than healthy women who have previously given birth.

Dr. Nelson says the persistence of these cells may indirectly dysregulate the mother's immune system interactions, somewhat like a computer virus disrupting the workings of a computer.

"Traditionally, the autoimmune diseases are described as your cells attacking your own normal, healthy tissue," Dr. Nelson, associate member of the Fred Hutchinson Cancer Research Center and associate professor of rheumatology at the University of Washington, explains. "Our findings," she continues, "raise the question as to whether some autoimmune diseases are not entirely autoimmune, whether they actually have a component that is non-self. It's really an entirely new paradigm." Dr. Nelson says the mix of self and non-self cells, a phenomenon known as chimerism, is somewhat analagous to what happens in a person who receives a non-identical bone marrow transplant and develops graft-versus-host disease (GVHD).

"These findings are intriguing," says Elaine Collier, M.D., chief of NIAID's autoimmunity section, "because they offer another potential explanation, in addition to sex hormones, for the higher incidence of autoimmune diseases in women. While these data are not definitive, they are provocative because of their implications."

Scleroderma, or systemic sclerosis, affects people of all races, with an estimated incidence of 14.1 cases per million population worldwide. Its cause remains unknown. The disease is at least three times more common in women than
'"/>

Contact: Laurie K. Doepel
ldoepel@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
19-Feb-1998


Page: 1 2 3 4

Related biology news :

1. Fetal lungs provide a signal initiating labor, UT Southwestern researchers find
2. Fetal death, miscarriage linked to genetic mutation
3. CDC MMWR: Fetal Alcohol Syndrome and Cutaneous Anthrax in a Lab Worker
4. Fetal research first in USA
5. Fetal and prepubertal growth both programme cholesterol metabolism in adulthood
6. Fetal and birth complications increase mental illness risks
7. Functional Arteries Grown From Cells Using Novel System That Simulates Fetal Environment
8. Study Suggests Maternal Stress And Stress Hormones May Influence Fetal Brain Development In Utero
9. Maternal Anxiety May Affect Fetal Development
10. Fetal Surgery For Spina Bifida Still Under Investigation At VUMC
11. Fetal Growth Rate Affects Risk Of Heart Disease

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Leftover Fetal Cells May Affect Development Scleroderma

(Date:6/18/2015)... 18, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market announces that its Wocket® smart ... "Money on the Mark", scheduled to air on WABC Radio ... 20 th . The broadcast air- time ... to 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira ...
(Date:6/17/2015)... GARDENS, Fla. , June 17, 2015 /PRNewswire/ ... solutions, today announced that its U.are.U ® ... Togo,s Eateries, Inc., a ... casual sandwich chain, to increase security, improve accountability ... fingerprint readers enable instant, non-repudiable identity confirmation for ...
(Date:6/16/2015)... Sweden , June 16, 2015 ... from previously communicated that it will amount to at least ... MSEK. Due to the rapid increase in market growth and ... the previously communicated guidance that revenue for 2015 will exceed ... will amount to approximately 2,200 MSEK. Due to ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
(Date:6/30/2015)... BOSTON , June 30, 2015  Juniper ... company focused on developing therapeutics that address unmet ... CFO George Elston will present at ... , Wednesday, July 8, 2015Time: , 4:45 PM ... NYWebcast (live & archive): , www.juniperpharma.com, under  ...
(Date:6/30/2015)... ... June 30, 2015 , ... With its latest polyacrylonitrile ... to achieve faster flow rates in comparison to nylon or polyethersulfone (PES). ... to allow easy liquid flow while trapping particulates as small as 0.2 micron ...
(Date:6/30/2015)... , ... June 30, 2015 , ... Matrix Marketing ... that it has hired Gem Swartz to head up its account management department as ... director. Both Gem and Amanda bring senior account management and delivery expertise to the ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company focused on the development ... participant in its Phase 1/2 clinical trial of ... unilateral Achilles tendinosis, has been enrolled and their ... ultrasound-guided injections. RCT-01 is comprised of non-bulbar dermal ...
Breaking Biology Technology:Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2Matrix Marketing Group Expands Client Services Team 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4
Cached News: